{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:18:53Z","timestamp":1791472733126,"version":"4.3.4"},"reference-count":195,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica (ANPCyT)","award":["PICT2021-0585"],"award-info":[{"award-number":["PICT2021-0585"]}]},{"name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica (ANPCyT)","award":["PIP 2232"],"award-info":[{"award-number":["PIP 2232"]}]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","award":["PICT2021-0585"],"award-info":[{"award-number":["PICT2021-0585"]}]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","award":["PIP 2232"],"award-info":[{"award-number":["PIP 2232"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by ineffective hematopoiesis, resulting in cytopenias, morphologic dysplasia in hematopoietic lineages, and a variable risk of progression to acute myeloid leukemia. Significant advances in the understanding of MDS have been made in recent years, largely due to the implementation of molecular tools. Latin America is a highly diverse region, both ethnically and racially, and often faces resource limitations that challenge the broad applicability of recent advances in MDS. In this review, we discuss the key genes implicated in the pathogenesis and classification of MDS, and their relevance to diagnosis, prognosis, and potential therapeutic targets. We also explore the challenges associated with the identification of germline predisposition to MDS in Latin America and discuss the current availability and limitations of molecular diagnostic tools in the region.<\/jats:p>","DOI":"10.3390\/genes16060687","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:27:09Z","timestamp":1748867229000},"page":"687","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-5543","authenticated-orcid":false,"given":"Ana Lisa","family":"Basquiera","sequence":"first","affiliation":[{"name":"Hospital Privado Universitario de C\u00f3rdoba, Instituto Universitario de Ciencias Biom\u00e9dicas de C\u00f3rdoba (IUCBC), X5016 C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1995-8518","authenticated-orcid":false,"given":"Ver\u00f3nica","family":"Andreoli","sequence":"additional","affiliation":[{"name":"Hospital Privado Universitario de C\u00f3rdoba, Instituto Universitario de Ciencias Biom\u00e9dicas de C\u00f3rdoba (IUCBC), X5016 C\u00f3rdoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Grille","sequence":"additional","affiliation":[{"name":"Unidad Acad\u00e9mica de Hematolog\u00eda, Hospital de Cl\u00ednicas, Universidad de la Rep\u00fablica, 11300 Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina B\u00e1rbara","family":"Belli","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Experimental (IMEX-CONICET\/ANM), C1425 AUM Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-013-1848-4","article-title":"Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients","volume":"93","author":"Belli","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: Development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"485","article-title":"Myelodysplasia-Related Mortality Remains the Main Cause of Death Along Different Groups of Risks: An Analysis from MDS Argentinean Study Group","volume":"102","author":"Basquiera","year":"2017","journal-title":"Haematologica"},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network (2025, April 13). Myelodysplastic Syndromes (Version 2.2025). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-022-00280-3","article-title":"Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells","volume":"11","author":"Luo","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gou, X., Chen, Z., and Shangguan, Y. (2025). Global, regional, and national burden of myelodysplastic syndromes and myeloproliferative neoplasms, 1990\u20132021: An analysis from the global burden of disease study 2021. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1559382"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1080\/10428194.2022.2032034","article-title":"The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: A population-based analysis","volume":"63","author":"Goksu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","unstructured":"(2025, April 07). Economic Commission for Latin America and the Caribbean (ECLAC). Demographic Observatory, 2024 (LC\/PUB.2024\/22-P), Santiago, 2024. Available online: https:\/\/repositorio.cepal.org\/server\/api\/core\/bitstreams\/dc566b9e-b3ef-44e9-a167-995614696404\/content."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/bloodadvances.2018GS110862","article-title":"Myelodysplastic syndromes in Latin America: State of the art","volume":"2","author":"Crisp","year":"2018","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1186\/s12864-018-5195-7","article-title":"Genetic ancestry, admixture and health determinants in Latin America","volume":"19","author":"Norris","year":"2018","journal-title":"BMC Genom."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.htct.2021.08.002","article-title":"Functional polymorphisms of DNA repair genes in Latin America reinforces the heterogeneity of Myelodysplastic Syndrome","volume":"45","author":"Borges","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.19689","article-title":"Molecular monitoring of myelodysplastic neoplasm: Don\u2019t just watch this space, consider the patient\u2019s ancestry","volume":"205","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.24097","article-title":"Myelodysplastic syndromes in South America: A multinational study of 1080 patients","volume":"90","author":"Belli","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00277-021-04539-3","article-title":"Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: A multicenter study of 280 patients","volume":"100","author":"Gonzalez","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2021.07.026","article-title":"Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients","volume":"22","author":"Azevedo","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1002\/ajh.25987","article-title":"Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients","volume":"95","author":"Lazzarino","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clml.2024.02.003","article-title":"Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers","volume":"24","author":"Castelo","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.6061\/clinics\/2019\/e771","article-title":"Prolonged response to recombinant human erythropoietin treatment in patients with myelodysplastic syndrome at a single referral centre in Brazil","volume":"74","author":"Moura","year":"2019","journal-title":"Clinics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/1607845415Y.0000000028","article-title":"Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO)","volume":"21","author":"Basquiera","year":"2016","journal-title":"Hematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2020.01.030","article-title":"Impact of Treatment Prior to Allogeneic Transplantation of Hematopoietic Stem Cells in Patients with Myelodysplastic Syndrome: Results of the Latin American Bone Marrow Transplant Registry","volume":"26","author":"Duarte","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjh.19614","article-title":"Monitoring molecular changes in the management of myelodysplastic syndromes","volume":"205","author":"Duployez","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3343\/alm.2024.0089","article-title":"Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing","volume":"45","author":"Lincango","year":"2025","journal-title":"Ann. Lab. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Catal\u00e1n, A.I., Boada, M., Ottati, C., Ranero, S., Cayota, A., Lens, D., and Grille, S. (2025). Integration of NGS and CNV Analysis in Prognostic Evaluation of MDS in a Developing Country: Insights from Uruguay. Blood Glob. Hematol., 100014. Available online: https:\/\/ashpublications.org\/bloodglobal\/article\/doi\/10.1016\/j.bglo.2025.100014\/537254\/Integration-of-NGS-and-CNV-Analysis-in-Prognostic.","DOI":"10.1016\/j.bglo.2025.100014"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.seminhematol.2024.10.005","article-title":"RNA splicing as a therapeutic target in myelodysplastic syndromes","volume":"61","author":"Tseng","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ajcp\/aqw016","article-title":"Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia","volume":"145","author":"Reinig","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/ajh.24901","article-title":"Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3960\/jslrt.23021","article-title":"Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome","volume":"63","author":"Nagehan","year":"2023","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jiang, M., Chen, M., Liu, Q., Jin, Z., Yang, X., and Zhang, W. (2023). SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1116438"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.2020004850","article-title":"SF3B1-mutant MDS as a distinct disease subtype: A proposal from the International Working Group for the Prognosis of MDS","volume":"136","author":"Malcovati","year":"2020","journal-title":"Blood"},{"key":"ref_40","first-page":"98","article-title":"Bioinformatic Evaluation of Differentially Expressed Genes in Myelodysplastic Syndromes with SF3B1 Variants","volume":"82","author":"Lincango","year":"2022","journal-title":"Medicina"},{"key":"ref_41","first-page":"108","article-title":"Validation of Novel Hub Genes Expression in Patients with Myelodysplastic Syndrome and SF3B1 Mutations","volume":"84","author":"Lincango","year":"2024","journal-title":"Medicina"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.bjhh.2016.06.002","article-title":"Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: A Brazilian cohort screening study","volume":"38","author":"Donaires","year":"2016","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1080\/10428194.2021.1941925","article-title":"Efficacy of lenalidomide in a patient with systemic mastocytosis associated with SF3B1-mutant myelodysplastic syndrome","volume":"62","author":"Sarmiento","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-023-00922-7","article-title":"U2AF1 pathogenic variants in myeloid neoplasms and precursor states: Distribution of co-mutations and prognostic heterogeneity","volume":"13","author":"Badar","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics\u2014An analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","article-title":"Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes","volume":"29","author":"Thol","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e6871","DOI":"10.1002\/cam4.6871","article-title":"Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Yang","year":"2024","journal-title":"Cancer Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/10245332.2015.1106815","article-title":"Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis","volume":"21","author":"Lin","year":"2016","journal-title":"Hematology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Rinke, J., Chase, A., Cross, N.C.P., Hochhaus, A., and Ernst, T. (2020). EZH2 in Myeloid Malignancies. Cells, 9.","DOI":"10.3390\/cells9071639"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106999","DOI":"10.1016\/j.leukres.2022.106999","article-title":"Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients","volume":"124","author":"Ball","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2012-11-469619","article-title":"BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders","volume":"122","author":"Damm","year":"2013","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2021010958","article-title":"BCOR gene alterations in hematologic diseases","volume":"138","author":"Sportoletti","year":"2021","journal-title":"Blood"},{"key":"ref_56","first-page":"1779","article-title":"Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms","volume":"109","author":"Baranwal","year":"2024","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2392469","DOI":"10.1080\/16078454.2024.2392469","article-title":"Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations","volume":"29","author":"Liu","year":"2024","journal-title":"Hematology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wei, Q., Hu, S., Xu, J., Loghavi, S., Daver, N., Toruner, G.A., Wang, W., Medeiros, L.J., and Tang, G. (2024). Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes. Cancers, 16.","DOI":"10.3390\/cancers16244193"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-023-00894-8","article-title":"Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification","volume":"13","author":"Lee","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-025-01231-x","article-title":"Myeloid neoplasms with PHF6 mutations: Context-dependent genomic and prognostic characterization in 176 informative cases","volume":"15","author":"Fathima","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zuo, Z., Medeiros, L.J., Garces, S., Routbort, M.J., Ok, C.Y., Loghavi, S., Kanagal-Shamanna, R., Jelloul, F.Z., Garcia-Manero, G., and Chien, K.S. (2022). Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology, 12.","DOI":"10.3390\/biology12010013"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/10428194.2024.2400210","article-title":"Untangling the loops of STAG2 mutations in myelodysplastic syndrome","volume":"66","author":"Sudunagunta","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/bloodadvances.2022007937","article-title":"Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: The Mayo Clinic experience","volume":"7","author":"Katamesh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2024024069","article-title":"\u201cRing-form\u201d megakaryocytic dysplasia in STAG2-mutated myelodysplastic neoplasm","volume":"143","author":"Deb","year":"2024","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-024-01607-9","article-title":"Landscape of biallelic DNMT3A mutant myeloid neoplasms","volume":"17","author":"Kawashima","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.26799","article-title":"Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome\/acute myeloid leukemia based on the 2022 International Consensus Classification","volume":"98","author":"Lee","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3026(22)00323-4","article-title":"A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: A multicentre, observational cohort study","volume":"10","author":"Maggioni","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jawad, M., Afkhami, M., Ding, Y., Zhang, X., Li, P., Young, K., Xu, M.L., Cui, W., Zhao, Y., and Halene, S. (2022). DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.849376"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","article-title":"TET (Ten-eleven translocation) family proteins: Structure, biological functions and applications","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e70792","DOI":"10.1002\/cam4.70792","article-title":"Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors","volume":"14","author":"Hawking","year":"2025","journal-title":"Cancer Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Danishevich, A., Chegodar, A., Bodunova, N., Konovalov, F., Nefedova, M., Kremneva, N., Kurbanov, N., Bilyalov, A., Nikolaev, S., and Khatkov, I. (2024). Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the TET2 Gene. Life, 14.","DOI":"10.3390\/life14050637"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/bloodadvances.2018024216","article-title":"Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia","volume":"3","author":"Awada","year":"2019","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.htct.2020.10.967","article-title":"Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes","volume":"44","author":"Bezerra","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3324\/haematol.2022.281607","article-title":"IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy","volume":"108","author":"Komrokji","year":"2023","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000479546","article-title":"IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes","volume":"138","author":"Wang","year":"2017","journal-title":"Acta Haematol."},{"key":"ref_83","first-page":"2157","article-title":"Patterns of lower risk myelodysplastic syndrome progression: Factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"109","author":"Jain","year":"2024","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bellissimo, D.C., and Speck, N.A. (2017). RUNX1 Mutations in Inherited and Sporadic Leukemia. Front. Cell Dev. Biol., 5.","DOI":"10.3389\/fcell.2017.00111"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.31557\/APJCP.2022.23.4.1107","article-title":"Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis","volume":"23","author":"Sutandyo","year":"2022","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/16078454.2020.1858598","article-title":"Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: A meta-analysis","volume":"25","author":"He","year":"2020","journal-title":"Hematology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/jha2.547","article-title":"Higher RUNX1 expression levels are associated with worse overall and leukaemia-free survival in myelodysplastic syndrome patients","volume":"3","author":"Wang","year":"2022","journal-title":"EJHaem"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Watad, A., Kacar, M., Bragazzi, N.L., Zhou, Q., Jassam, M., Taylor, J., Roman, E., Smith, A., Jones, R.A., and Amital, H. (2021). Somatic Mutations and the Risk of Undifferentiated Autoinflammatory Disease in MDS: An Under-Recognized but Prognostically Important Complication. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.610019"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1093\/rheumatology\/keab513","article-title":"Somatic mutation in RUNX1 underlies mucocutaneus inflammatory manifestations","volume":"60","author":"Okano","year":"2021","journal-title":"Rheumatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ajcp\/aqab157","article-title":"Clinically Significant CUX1 Mutations Are Frequently Subclonal and Common in Myeloid Disorders With a High Number of Co-mutated Genes and Dysplastic Features","volume":"157","author":"Dermawan","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.gene.2012.01.039","article-title":"CUX1 transcription factors: From biochemical activities and cell-based assays to mouse models and human diseases","volume":"497","author":"Hulea","year":"2012","journal-title":"Gene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/bloodadvances.2018028423","article-title":"Distinct clinical and biological implications of CUX1 in myeloid neoplasms","volume":"3","author":"Aly","year":"2019","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.3324\/haematol.2014.104406","article-title":"ETV6 mutation in a cohort of 970 patients with hematologic malignancies","volume":"99","author":"Wang","year":"2014","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.18850","article-title":"The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms","volume":"202","author":"Gurney","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Olivier, M., Hollstein, M., and Hainaut, P. (2010). TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol., 2.","DOI":"10.1101\/cshperspect.a001008"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cll.2023.07.004","article-title":"Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53","volume":"43","author":"Siddon","year":"2023","journal-title":"Clin. Lab. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"107158","DOI":"10.1016\/j.leukres.2023.107158","article-title":"TP53 Myelodysplastic Syndromes in Latin America. Real World Data from Latin American MDS Group (GLAM)","volume":"128S","author":"Boada","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Fandrei, D., Pegliasco, J., Pasquier, F., Ibrahim, N., Kfoury, M., Berthon, C., Heiblig, M., Lebon, D., Marcais, A., and Meunier, M. (2025). Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders. Clin. Cancer Res., OF1\u2013OF13.","DOI":"10.1158\/1078-0432.c.7854116"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1111\/jcmm.17613","article-title":"Somatic mutations of activating signalling, transcription factor, and tumour suppressor are a precondition for leukaemia transformation in myelodysplastic syndromes","volume":"26","author":"Xu","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/2643-3230.BCD-21-0155","article-title":"Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression","volume":"3","author":"Menssen","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"106790","DOI":"10.1016\/j.leukres.2022.106790","article-title":"The FLT3 internal tandem duplication mutation at disease diagnosis is a negative prognostic factor in myelodysplastic syndrome patients","volume":"113","author":"Sumiyoshi","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"Kroeze","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.3099","article-title":"Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome","volume":"41","author":"Ren","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"103803","DOI":"10.1016\/j.dnarep.2024.103803","article-title":"The Ataxia-telangiectasia mutated (ATM) is the most important gene for repairing the DNA in Myelodysplastic Neoplasm","volume":"146","author":"Pinheiro","year":"2025","journal-title":"DNA Repair"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/sj.onc.1210599","article-title":"HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention","volume":"26","author":"Yang","year":"2007","journal-title":"Oncogene"},{"key":"ref_108","first-page":"53","article-title":"Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins","volume":"3","author":"Dai","year":"2008","journal-title":"Transl. Oncogenomics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"148428","DOI":"10.1016\/j.gene.2024.148428","article-title":"Gene expression patterns of Sirtuin family members (SIRT1 TO SIRT7): Insights into pathogenesis and prognostic of Myelodysplastic neoplasm","volume":"915","author":"Goes","year":"2024","journal-title":"Gene"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1002\/hem3.145","article-title":"How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms","volume":"8","author":"Baliakas","year":"2024","journal-title":"Hemasphere"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1097\/HS9.0000000000000961","article-title":"Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes","volume":"7","author":"Mora","year":"2023","journal-title":"Hemasphere"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-023-01855-7","article-title":"MDS subclassification-do we still have to count blasts?","volume":"37","author":"Huber","year":"2023","journal-title":"Leukemia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1038\/s41467-023-38515-4","article-title":"Molecular patterns identify distinct subclasses of myeloid neoplasia","volume":"14","author":"Kewan","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100397","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood.2024025676","article-title":"Seeing MDS through the lens of genomics","volume":"144","author":"Vaughan","year":"2024","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.mayocp.2019.10.004","article-title":"Myelodysplastic Syndrome Over Time: A Comparative Analysis of Overall Outcome","volume":"94","author":"Mendonca","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.mayocp.2019.02.029","article-title":"Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study from 2004\u20132013","volume":"94","author":"Zblewski","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/hem3.70103","article-title":"Low-risk MDS-A spotlight on precision medicine for SF3B1-mutated patients","volume":"9","author":"Burke","year":"2025","journal-title":"Hemasphere"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2022008378","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","volume":"7","author":"DiNardo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/ajh.26694","article-title":"Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment","volume":"97","author":"Lachowiez","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.19105","article-title":"Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients","volume":"204","author":"Nanaa","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1080\/10428194.2022.2070913","article-title":"Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: A meta-analysis","volume":"63","author":"Hu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.23.02175","article-title":"Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes","volume":"42","author":"Tentori","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.2024025131","article-title":"Clinical-genomic profiling of MDS to inform allo-HCT: Recommendations from an international panel on behalf of the EBMT","volume":"145","author":"Gurnari","year":"2025","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline Mutations in Predisposition Genes in Pediatric Cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-017-01590-5","article-title":"The genomic landscape of pediatric myelodysplastic syndromes","volume":"8","author":"Schwartz","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"Sebert","year":"2019","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2016.04.001","article-title":"Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)","volume":"16","author":"DiNardo","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101537","DOI":"10.1016\/j.beha.2024.101537","article-title":"Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders","volume":"37","author":"Trottier","year":"2024","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2141.2007.06909.x","article-title":"Familial myelodysplasia and acute myeloid leukaemia\u2014A review","volume":"140","author":"Owen","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in familial acute myeloid leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: Further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","article-title":"DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease","volume":"94","author":"Quesada","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"ref_149","first-page":"103409","article-title":"Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogenetique hematologique (GFCH)","volume":"71","author":"Auger","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","article-title":"Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies","volume":"7","author":"Saygin","year":"2023","journal-title":"Blood Adv."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2008-05-156745","article-title":"Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy","volume":"112","author":"Owen","year":"2008","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/13793","article-title":"Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia","volume":"23","author":"Song","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood.V92.7.2600","article-title":"Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD\/AML)","volume":"92","author":"Arepally","year":"1998","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ejhg.2008.89","article-title":"Clinical phenotype of germline RUNX1 haploinsufficiency: From point mutations to large genomic deletions","volume":"16","author":"Philippe","year":"2008","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3109\/10428194.2010.503821","article-title":"Identification and molecular characterization of a novel 3\u2032 mutation in RUNX1 in a family with familial platelet disorder","volume":"51","author":"Churpek","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood.V99.4.1364","article-title":"In vitro analyses of known and novel RUNX1\/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis","volume":"99","author":"Michaud","year":"2002","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2017.1.385","article-title":"Hereditary thrombocytopenias: A growing list of disorders","volume":"2017","author":"Noris","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1182\/blood-2011-02-336537","article-title":"Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: Analysis of 78 patients from 21 families","volume":"117","author":"Noris","year":"2011","journal-title":"Blood"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2013-04-499319","article-title":"ANKRD26-related thrombocytopenia and myeloid malignancies","volume":"122","author":"Noris","year":"2013","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0382-y","article-title":"5\u2032UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia","volume":"10","author":"Marconi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/bloodadvances.2018030635","article-title":"Germline deletion of ETV6 in familial acute lymphoblastic leukemia","volume":"3","author":"Rampersaud","year":"2019","journal-title":"Blood Adv."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","article-title":"Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients","volume":"103","author":"Donadieu","year":"2018","journal-title":"Haematologica"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: A protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"101197","DOI":"10.1016\/j.beha.2020.101197","article-title":"Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9\/SAMD9L syndromes","volume":"33","author":"Sahoo","year":"2020","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2017-09-806489","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ng.3569","article-title":"SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7","volume":"48","author":"Narumi","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/jnci\/djae102","article-title":"Identification of TP53 germline variants in pediatric patients undergoing tumor testing: Strategy and prevalence","volume":"116","author":"Luo","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2007.10.044","article-title":"Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil","volume":"261","author":"Palmero","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/humu.21151","article-title":"Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: Evidence for a founder effect","volume":"31","author":"Garritano","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_176","first-page":"100982","article-title":"Personalized screening strategies for TP53 R337H carriers: A retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriers","volume":"42","author":"Galante","year":"2025","journal-title":"Lancet Reg. Health. Am."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2012.46.3711","article-title":"Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors","volume":"31","author":"Custodio","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"148069","DOI":"10.1016\/j.gene.2023.148069","article-title":"Functional pri-miR-34b\/c rs4938723 and KRAS 3\u2032UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?","volume":"898","author":"Vieira","year":"2024","journal-title":"Gene"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up","volume":"3","author":"Baliakas","year":"2019","journal-title":"Hemasphere"},{"key":"ref_180","unstructured":"(2025, April 07). Hemoterapia, S.E.d.H.y. Manual para el Diagn\u00f3stico y Atenci\u00f3n Cl\u00ednica en la Predisposici\u00f3n Germinal a Neoplasias Hematol\u00f3gicas. Available online: https:\/\/sehh.es\/publicaciones\/manuales-publicaciones\/126044-manual-para-el-diagnostico-y-atencion-clinica-en-la-predisposicion-germinal-a-neoplasias-hematologicas."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.2020006481","article-title":"Inherited bone marrow failure in the pediatric patient","volume":"140","author":"Dokal","year":"2022","journal-title":"Blood"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41436-020-0934-y","article-title":"Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies","volume":"23","author":"Roloff","year":"2021","journal-title":"Genet. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.24374","article-title":"Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders","volume":"43","author":"DeRoin","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/bloodadvances.2022007211","article-title":"Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations","volume":"6","author":"Drazer","year":"2022","journal-title":"Blood Adv."},{"key":"ref_185","first-page":"2100","article-title":"Differential diagnosis of bone marrow failure syndromes guided by machine learning","volume":"141","author":"Munger","year":"2023","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/bjh.19776","article-title":"Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD\/AML diagnosis","volume":"205","author":"Kamiya","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2023019746","article-title":"Natural history study of patients with familial platelet disorder with associated myeloid malignancy","volume":"142","author":"Cunningham","year":"2023","journal-title":"Blood"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10689-025-00443-1","article-title":"Myelodysplastic syndrome with dual germline RUNX1 and DDX41 variants: A rare genetic predisposition case","volume":"24","author":"Bove","year":"2025","journal-title":"Fam. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/cge.14693","article-title":"Unusual Co-Occurrence of Multiple Myeloma and AML in a Patient With Germline CEBPA Variant. Expanding the Spectrum of Hereditary Hematologic Malignancies","volume":"107","author":"Spangenberg","year":"2025","journal-title":"Clin. Genet."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.4081\/hr.2021.9114","article-title":"Germline CEBPA mutation in familial acute myeloid leukemia","volume":"13","author":"Boada","year":"2021","journal-title":"Hematol. Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"107143","DOI":"10.1016\/j.leukres.2023.107143","article-title":"P008-Topic: AS01-Diagnosis\/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): Real-world laboratory practice patterns on next-generation-sequencing (NGS) technology in Latin America","volume":"128","author":"Belli","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_192","first-page":"174","article-title":"Preferences and limitations of hematologists to address the complexity of myelodysplastic syndromes","volume":"79","author":"Crisp","year":"2019","journal-title":"Medicina"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ijlh.13047","article-title":"Flow cytometry \u201cOgata score\u201d for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience","volume":"41","author":"Velloso","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1182\/blood-2022-168893","article-title":"Myelodysplastic Syndromes in Latin-America\u2014Results from a Novel International Registry: Re-Glam","volume":"140","author":"Grille","year":"2022","journal-title":"Blood"},{"key":"ref_195","first-page":"312","article-title":"Genome sequencing in the management of myelodysplastic syndromes and related disorders","volume":"110","author":"Cazzola","year":"2025","journal-title":"Haematologica"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/6\/687\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:45:59Z","timestamp":1760031959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/6\/687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":195,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["genes16060687"],"URL":"https:\/\/doi.org\/10.3390\/genes16060687","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}